Related Experiment Videos
Antiblastic treatment does not affect N-myc gene amplification in neuroblastoma
G P Tonini1, G Verdona, A Garaventa
1Pediatric Oncology Research Laboratory, G. Gaslini Children's Hospital, Genoa, Italy.
Abstract:
Gene amplification has been found in the genome of cells growing in vivo and/or in vitro. In cell lines with acquired multidrug resistance gene amplification has been frequently detected. Moreover, extra-copies of cellular oncogenes have been located in tumor cells in vivo; particularly N-myc gene amplification was discovered in advanced stage of neuroblastoma (NB). Neuroblastoma, a tumor of neural origin, has a high incidence in children. N-myc amplification has been demonstrated in untreated patient and a positive significant correlation with the progression of the disease has been established. In this paper we report on four NB patients treated with a polychemotherapeutic protocol and showing N-myc amplification. One patient examined before and after treatment displayed a slight change in N-myc gene copy numbers. It was shown that N-myc gene amplification is not affected by drug activities and that minimal residual of cells bearing N-myc amplification may remain in the tumor mass. N-myc amplification can also cause advantageous cell growth in the presence of drugs. The implications in the pharmacologic management of NB patient showing N-myc gene amplification is discussed.
Insights
Gene amplification, particularly N-myc amplification in neuroblastoma (NB), is linked to disease progression. This study found N-myc amplification persists despite chemotherapy, potentially aiding drug-resistant cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gene amplification is observed in cells and frequently detected in multidrug-resistant cell lines.
- Extra copies of oncogenes, specifically N-myc gene amplification, are found in neuroblastoma (NB) tumor cells.
- N-myc amplification correlates significantly with advanced neuroblastoma progression in children.
Observation:
- Four neuroblastoma patients treated with polychemotherapy were analyzed for N-myc amplification.
- One patient showed minimal change in N-myc gene copy numbers before and after treatment.
Findings:
- N-myc gene amplification is largely unaffected by drug treatments in neuroblastoma.
- Residual cells with N-myc amplification may persist within the tumor mass post-treatment.
- N-myc amplification can confer a growth advantage to cells in the presence of chemotherapeutic agents.
Implications:
- N-myc amplification in neuroblastoma patients may necessitate tailored therapeutic strategies.
- Understanding N-myc amplification's role is crucial for optimizing pharmacologic management in neuroblastoma.
- The persistence and potential growth advantage of N-myc amplified cells impact treatment outcomes.